Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Condition: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
MeSH terms: Carcinoma; Lung Neoplasms
Intervention: Durvalumab; Laboratory Biomarker Analysis; Tremelimumab
Intervention description: Given IV; Correlative studies; Given IV
Intervention MeSH terms: Durvalumab; Ipilimumab; Tremelimumab; Immunoglobulins; Antibodies, Monoclonal; Immunoglobulin G
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 67.0
Sex: All
Healthy volunteers: No

Summary:

      This phase II trial studies how well durvalumab and tremelimumab works in treating patients
      with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies,
      such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow
      and spread.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have been assigned to S1400F

          -  Patients must have progressed during or after prior platinum-based chemotherapy;
             patients whose only prior platinum-based chemotherapy regimen was for stage I-III
             disease (i.e. patient has not received any platinum-based chemotherapy for stage IV or
             recurrent disease), disease progression on platinum-based chemotherapy must have
             occurred within one year from the last date that patient received that therapy;
             patients must have experienced disease progression during or after prior anti-PD-1 or
             anti-PD-L1 antibody monotherapy as their most recent line of treatment; prior
             PD-1/PD-L1 combination therapy is not permitted

          -  Prior exposure to CTLA-4 inhibitors (ipilimumab and tremelimumab) is not permitted;
             prior exposure to the following is allowed: attenuated vaccines, anti-EGFR agents, and
             granulocyte-macrophage colony-stimulating factor (GM-CSF)

          -  Patients must not have received nitrosoureas or mitomycin-C within 42 days prior to
             sub-study registration

          -  Patients must not have any prior documented autoimmune or inflammatory disease
             (including inflammatory bowel disease, diverticulitis with the exception of
             diverticulosis, celiac disease, irritable bowel disease; Wegner syndrome; Hashimoto
             syndrome) within 3 years prior to sub-study registration; patients with vitiligo,
             immune-mediated alopecia, Grave?s disease, or psoriasis requiring systemic treatment
             within the past 2 years are not eligible; patients with hypothyroidism (e.g. post
             Hashimoto syndrome) who are stable on hormone replacement therapy are eligible

          -  Patients must not have any history of primary immunodeficiency

          -  Patients must not have received any immunosuppressive medication within 28 days prior
             to sub-study registration and must not be planning to receive these medications while
             on protocol therapy; systemic corticosteroids must be stopped at least 24 hours prior
             to sub-study registration; however, intranasal and inhaled corticosteroids are allowed
             at any time before and during protocol therapy

          -  Patients must not have experienced a grade 3 or worse immune-related adverse event
             (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved irAE
             grade 2, nor have experienced a toxicity that led to permanent discontinuation of
             prior anti-PD-1/PD-L1 immunotherapy

          -  Patients must not have any history of organ transplant that requires use of
             immunosuppressives

          -  Patients must not have any known allergy or reaction to any component of the
             durvalumab (MEDI4736) and/or tremelimumab formulation

          -  Patients must not have clinical signs or symptoms of active tuberculosis infection

          -  Patients must not have received a live attenuated vaccination within 28 days prior to
             sub-study registration

          -  Patients must not have known human immunodeficiency virus (HIV), or a known positive
             test for hepatitis B virus surface antigen (HBV sAg), or hepatitis C virus ribonucleic
             acid (HCV antibody) indicating current acute or chronic infection; patients with a
             positive hepatitis C antibody with a negative viral load are allowed

          -  Patients must have a thyroid-stimulating hormone (TSH) with reflex free T3/free T4 (if
             TSH is out of normal range) and electrocardiogram (EKG) obtained within 7 days prior
             to sub-study registration

          -  Patients must also be offered participation in banking and in the correlative studies
             for collection and future use of specimens